Zoetis Inc. (ZTS) Return on Assets (ROA): 17.44%
Is Zoetis Inc.’s return on assets (ROA) high or low?
Zoetis Inc.'s return on assets (ROA) of 17.44% is 14% above its 5-year average of 15.33%, near the high end of its 5-year range (12.04%–17.46%).
The return on assets (ROA) for Zoetis Inc. (ZTS) is 17.44% as of Wednesday, June 10, 2026. It is above its 12-month average by 0.40% (17.37%).
ZTS Return on Assets (ROA) Chart
ZTS Average Return on Assets (ROA) Chart
ZTS Current vs Average Return on Assets (ROA) Chart
ZTS Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
17.44%
RETURN ON ASSETS (ROA) AVG TTM
17.37%
RETURN ON ASSETS (ROA) AVG 3Y
16.33%
RETURN ON ASSETS (ROA) AVG 5Y
15.33%
RETURN ON ASSETS (ROA) AVG 10Y
13.03%
RETURN ON ASSETS (ROA) AVG 15Y
10.82%
RETURN ON ASSETS (ROA) AVG 20Y
10.19%
CURRENT VS TTM AVG
+0.40%
CURRENT VS 3Y AVG
+6.81%
CURRENT VS 5Y AVG
+13.74%
CURRENT VS 10Y AVG
+33.86%
CURRENT VS 15Y AVG
+61.13%
CURRENT VS 20Y AVG
+71.20%
ZTS Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zoetis Inc. (ZTS) | — | 17.44% | 17.37% | 16.33% | 15.33% |
| Centene Corporation (CNC) | $31.94B | -7.94% | -2.29% | 0.04% | 0.75% |
| Agilent Technologies, Inc. (A) | $37.17B | 10.82% | 10.56% | 11.14% | 10.55% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 4.67% | 4.82% | 4.76% | 4.01% |
| DexCom, Inc. (DXCM) | $29.24B | 14.03% | 11.04% | 9.26% | 8.83% |
| Biogen Inc. (BIIB) | $29.00B | 4.65% | 5.11% | 6.74% | 8.29% |
| Veeva Systems Inc. (VEEV) | $26.73B | 10.31% | 9.93% | 9.72% | 10.43% |
| Humana Inc. (HUM) | $43.78B | 2.04% | 2.52% | 4.20% | 5.49% |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 32.35% | 29.29% | 27.30% | 27.52% |
| Waters Corporation (WAT) | $23.83B | 1.83% | 13.34% | 15.53% | 17.15% |
Asset Efficiency
ROA
17.4%
ROE
81.8%
Zoetis Inc. Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for Zoetis Inc. (ZTS)?
- The return on assets (ROA) for ZTS stock is 17.44%.
- Is Zoetis Inc.'s return on assets (ROA) high or low?
- Zoetis Inc.'s return on assets (ROA) of 17.44% is 14% above its 5-year average of 15.33%, near the high end of its 5-year range (12.04%–17.46%).
- What is the TTM average return on assets (ROA) for Zoetis Inc. (ZTS)?
- The TTM average return on assets (ROA) for ZTS stock is 17.37%.
- What is the 3Y average return on assets (ROA) for Zoetis Inc. (ZTS)?
- The 3Y average return on assets (ROA) for ZTS stock is 16.33%.
- What is the 5Y average return on assets (ROA) for Zoetis Inc. (ZTS)?
- The 5Y average return on assets (ROA) for ZTS stock is 15.33%.
- What is the 10Y average return on assets (ROA) for Zoetis Inc. (ZTS)?
- The 10Y average return on assets (ROA) for ZTS stock is 13.03%.
- What is the 15Y average return on assets (ROA) for Zoetis Inc. (ZTS)?
- The 15Y average return on assets (ROA) for ZTS stock is 10.82%.
- What is the 20Y average return on assets (ROA) for Zoetis Inc. (ZTS)?
- The 20Y average return on assets (ROA) for ZTS stock is 10.19%.
Zoetis Inc. Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 17.28% |
| 2024-12-31 | 17.46% |
| 2023-12-31 | 16.41% |
| 2022-12-31 | 14.16% |
| 2021-12-31 | 14.65% |
| 2020-12-31 | 12.04% |
| 2019-12-31 | 12.99% |
| 2018-12-31 | 13.25% |
| 2017-12-31 | 10.06% |
| 2016-12-31 | 10.73% |
| 2015-12-31 | 4.28% |
| 2014-12-31 | 8.85% |
| 2013-12-31 | 7.69% |
| 2012-12-31 | 6.96% |
| 2011-12-31 | 4.29% |
| 2010-12-31 | 2.08% |
| 2009-12-31 | 0.00% |
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck